Cat Allergy - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 36

Cat Allergy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cat Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cat Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cat Allergy. Cat Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cat Allergy.
- A review of the Cat Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cat Allergy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cat Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cat Allergy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cat Allergy 7
Cat Allergy Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Cat Allergy Therapeutics – Products under Development by Companies 13
Companies Involved in Cat Allergy Therapeutics Development 14
ALK-Abello A/S 14
Circassia Holdings Ltd. 15
ImVisioN Therapeutics AG 16
Biomay AG 17
Cat Allergy – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
ToleroMune Cat Allergy T Cell Vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
IVN-201 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Cat Allergen Peptide Carrier Fusion Vaccine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Cat Allergen RNA Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Cat Allergen Hypoallergenic Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Cat Allergy Therapeutics – Drug Profile Updates 31
Cat Allergy – Product Development Milestones 32
Featured News & Press Releases 32
Jun 13, 2011: Circassia's Rapid Four-Dose ToleroMune Treatment Maintains Significant Reduction In Allergy Symptoms During 12-Month Follow-up 32
Feb 01, 2011: Circassia's ToleroMune T-cell Vaccine Achieves Significant Reduction In Allergy Symptoms In Key Phase II Clinical Study 32
Jan 19, 2010: Circassia Extends Its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite And Cat Allergies 33
Nov 20, 2009: Circassia Announces Successful Results From Phase II Clinical Study Of ToleroMune Cat Allergy Therapy 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Number of Products Under Development for Cat Allergy, H2 2012 7
Products under Development for Cat Allergy – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
ALK-Abello A/S, H2 2012 14
Circassia Holdings Ltd., H2 2012 15
ImVisioN Therapeutics AG, H2 2012 16
Biomay AG, H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Cat Allergy Therapeutics – Drug Profile Updates 31

List of Figures
Number of Products under Development for Cat Allergy, H2 2012 7
Products under Development for Cat Allergy – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Discovery and Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Customers who bought this item also bought

• Allergies - Pipeline Review, H2 2012
• Peanut Allergy - Pipeline Review, H2 2012
• Pollen Allergy - Pipeline Review, H2 2012
• Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Dyslipidemia - Pipeline Review, H2 2012